170 related articles for article (PubMed ID: 12065865)
21. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
23. [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].
Zabalegui N; López Díaz de Cerio A; Inogés S; Soria E; Villanueva H; Rivero P
An Sist Sanit Navar; 2009; 32(1):61-73. PubMed ID: 19430512
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
25. Idiotype vaccine strategies for treatment of follicular lymphoma.
Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
[TBL] [Abstract][Full Text] [Related]
26. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation.
Kwak LW
Ann Oncol; 1998; 9 Suppl 1():S41-6. PubMed ID: 9581240
[TBL] [Abstract][Full Text] [Related]
27. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
Marron TU; Ronner L; Martin PE; Flowers CR; Brody JD
Immunotherapy; 2016 Nov; 8(11):1335-1346. PubMed ID: 27993085
[TBL] [Abstract][Full Text] [Related]
28. Idiotype vaccines for human B-cell malignancies.
Inoges S; de Cerio AL; Soria E; Villanueva H; Pastor F; Bendandi M
Curr Pharm Des; 2010 Jan; 16(3):300-7. PubMed ID: 20109139
[TBL] [Abstract][Full Text] [Related]
29. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
Flowers CR
Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic vaccines for non-Hodgkin B-cell lymphoma.
Briones J
Clin Transl Oncol; 2008 Sep; 10(9):543-51. PubMed ID: 18796371
[TBL] [Abstract][Full Text] [Related]
31. T cell mediated immunotherapy for B cell lymphoma.
Schultze JL; Nadler LM
J Mol Med (Berl); 1999 Mar; 77(3):322-31. PubMed ID: 10090595
[TBL] [Abstract][Full Text] [Related]
32. New strategies for vaccination and imunomodulation in NHL.
Stevenson FK; Zhu D; Rice J
Ann Hematol; 2001; 80 Suppl 3():B132-4. PubMed ID: 11757697
[TBL] [Abstract][Full Text] [Related]
33. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
Baskar S; Kobrin CB; Kwak LW
J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic vaccine for lymphoma.
Lee ST; Neelapu SS; Kwak LW
Yonsei Med J; 2007 Feb; 48(1):1-10. PubMed ID: 17326239
[TBL] [Abstract][Full Text] [Related]
35. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
Reinis M
Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
[TBL] [Abstract][Full Text] [Related]
36. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
Qin H; Cha SC; Neelapu SS; Lou Y; Wei J; Liu YJ; Kwak LW
Blood; 2009 Nov; 114(19):4142-9. PubMed ID: 19749091
[TBL] [Abstract][Full Text] [Related]
37. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for non-Hodgkin's lymphoma.
Vose JM
Oncology (Williston Park); 2001 Feb; 15(2):141-7, 151; discussion 152-5. PubMed ID: 11252930
[TBL] [Abstract][Full Text] [Related]
39. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
Mocikat R; Selmayr M; Thierfelder S; Lindhofer H
Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805
[TBL] [Abstract][Full Text] [Related]
40. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
Rhee Fv
Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
